ALB and malignant colon neoplasm: Thisstudy reports on the first triple-action prodrugs of oxaliplatin,which is the current state of the art therapy against colon cancer.2 To this end, we used well-established platinum(IV)prodrugs (which themselves have often insufficient targeting propertiesdue to premature activation in e.g. red blood cells) and improvedtheir tumor delivery by attaching an albumin-targeting maleimide moietyas one axial ligand.